Mobile

Randomized, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20-mg od, for inhibition of atherosclerosis progression assessed by carotid artery intima-media th...

Update Il y a 4 ans
Reference: EUCTR2005-001612-49

Randomized, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20-mg od, for inhibition of atherosclerosis progression assessed by carotid artery intima-media thickness (CIMT), in overweight patients with additional risk factors

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the effect of rimonabant 20-mg once daily in comparison with placebo, on the quantitative progression of atherosclerosis as assessed by CIMT.

Inclusion criteria

  • Overweight patients with additional risk factors. Atherosclerosis progression assessed by carotid artery intima-media thickness (CIMT)

Links